HALO - Halozyme Therapeutics, Inc.
18.85 -0.06 (-0.30%)
After hours: 4:11PM EST
| Previous Close | 18.49 |
| Open | 18.43 |
| Bid | 18.93 x 3200 |
| Ask | 18.94 x 900 |
| Day's Range | 18.40 - 19.05 |
| 52 Week Range | 13.24 - 19.05 |
| Volume | 3,297,881 |
| Avg. Volume | 1,254,712 |
| Market Cap | 2.9B |
| Beta (3Y Monthly) | 1.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.28 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.30 |
- Benzinga
The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
- Zacks
Halozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in Session
Halozyme Therapeutics (HALO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- PR Newswire
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024
SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of $400.0 million aggregate principal amount of its convertible senior notes due 2024 (the "Convertible Notes"). The Convertible Notes are being offered in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company granted an option to the initial purchasers to purchase up to an additional $60.0 million aggregate principal amount of Convertible Notes.
- Zacks
Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3
Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.
- Zacks
Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -41.67% and -21.40%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Bernadette Connaughton Appointed to Syneos Health Board of Directors
MORRISVILLE, N.C., Nov. 12, 2019 -- Syneos Health® (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a.
- PR Newswire
Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced that it intends to offer, subject to market conditions and other factors, $400 million aggregate principal amount of convertible senior notes due 2024 (the "Convertible Notes"). The Convertible Notes are to be offered and sold to "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company also expects to grant a 30-day option to the initial purchasers to purchase up to an additional $60 million aggregate principal amount of Convertible Notes.
- PR Newswire
Halozyme Reports Third Quarter 2019 Results
- Total Revenues Increase 81% to $46.2 million Compared to $25.6 million in Prior-year Period - - First Quarter of Sustainable Profitability Expected in Second Quarter of 2020 - - Board Authorizes Initiation ...
- Schaeffer's Investment Research
Long-Term Signal Says Buy This Biotech
HALO puts have been popular recently
- Zacks
Halozyme Therapeutics (HALO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Benzinga
Halozyme Scraps Oncology Program Following Failed Study, Charts Out Profitability Plan
The treatment arm, which evaluated PEGPH20 in combination with chemotherapy drugs gemcitabine and nab—paclitaxel, did not show an improvement in median overall survival compared to the chemotherapy drugs alone, the company said. With the PEGPH20 program shelved, Halozyme announced strategic actions to reposition as a company focusing solely on its ENHANZE drug delivery technology. "Our mission now is to transition our strategy to focus on our high-growth, high-margin ENHANZE drug delivery technology platform," CEO Dr. Helen Torley said in a statement.
- PR Newswire
Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology
SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) today announced strategic actions to reposition the Company with a focus solely on its ENHANZE® drug delivery technology. In order to implement this strategic shift, Halozyme will immediately initiate an organizational restructuring to halt development activities for PEGPH20 and close its oncology operations. Restructuring and other cost saving efforts will result in savings of $130 to $140 million in 2020 compared with the Company's most recent guidance for 2019 operating expenses excluding cost of goods sold.
- PR Newswire
Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint
SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreas cancer failed to reach the primary endpoint of overall survival. The treatment arm of PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE®) failed to demonstrate an improvement in median overall survival compared to gemcitabine and nab-paclitaxel alone (11.2 months compared to 11.5 months, HR=1.00, p=0.9692). "Patients in both treatment arms of the HALO-301 trial surpassed the published median overall survival rates from the pivotal registration study of ABRAXANE® plus gemcitabine as first-line therapy for metastatic pancreas cancer, published in 2013.
- Simply Wall St.
Do Institutions Own Shares In Halozyme Therapeutics, Inc. (NASDAQ:HALO)?
If you want to know who really controls Halozyme Therapeutics, Inc. (NASDAQ:HALO), then you'll have to look at the...
- Insider Monkey
is Halozyme Therapeutics, Inc. (HALO) Going To Burn These Hedge Funds?
Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]
- PR Newswire
Halozyme To Host Third Quarter 2019 Financial Results Webcast And Conference Call
SAN DIEGO , Oct. 21, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
- Simply Wall St.
How Many Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Have Insiders Sold, In The Last Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- PR Newswire
Halozyme To Participate In 2019 Cantor Global Healthcare Conference
SAN DIEGO , Sept. 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Cantor ...
- Thomson Reuters StreetEvents
Edited Transcript of HALO earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 Halozyme Therapeutics Inc Earnings Call
- Zacks
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
- PR Newswire
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology
- Phase III FeDeriCa Study Met Primary Endpoint of Non-inferiority - - New Subcutaneous Fixed-dose Combination Significantly Reduced Administration Time - - Data to be Submitted to Health Authorities including ...
- Simply Wall St.
Why Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) CEO Pay Matters To You
Helen Torley has been the CEO of Halozyme Therapeutics, Inc. (NASDAQ:HALO) since 2014. This analysis aims first to...
- PR Newswire
Halozyme To Participate In 2019 Wells Fargo Healthcare Conference
SAN DIEGO , Aug. 26, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Wells Fargo ...
Motley FoolHalozyme Therapeutics Inc (HALO) Q2 2019 Earnings Call Transcript
HALO earnings call for the period ending June 30, 2019.
- Zacks
Halozyme Therapeutics (HALO) Reports Q2 Loss, Lags Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 41.18% and -0.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
